Compounds > syntometrine
Page last updated: 2024-11-12

syntometrine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

syntometrine: mixture of above cpds (1:1) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11979741
SCHEMBL ID15511131
MeSH IDM0115502

Synonyms (8)

Synonym
oxytocin, mixt. with (8beta)-9,10-didehydro-n-(1s)-2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide (2z)-2-butenedioate (1:1) (salt)
syntometrine
ergoline-8-carboxamide, 9,10-didehydro-n-(2-hydroxy-1-methylethyl)-6-methyl-, (8beta(s))-, (z)-2-butenedioate (1:1) (salt), mixt. with oxytocin
oxymetrin
37209-62-4
SCHEMBL15511131
oxytocin/ergometrine
Q7116181

Research Excerpts

Overview

Syntometrine is an effective uterotonic agent used in preventing primary postpartum haemorrhage. It has adverse effects including nausea, vomiting, hypertension and coronary artery spasm.

ExcerptReferenceRelevance
"Syntometrine is an effective uterotonic agent used in preventing primary postpartum haemorrhage but has adverse effects including nausea, vomiting, hypertension and coronary artery spasm. "( A randomised trial of carbetocin versus syntometrine in the management of the third stage of labour.
Cheung, TH; Leung, SW; Ng, PS; Wong, WY, 2006)		2.04
"Syntometrine is an effective and commonly used oxytocic in preventing postpartum haemorrhage, but it requires a controlled storage environment and i.m."( A multicentre randomized controlled trial of oral misoprostol and i.m. syntometrine in the management of the third stage of labour.
Chan, AS; Cheung, KB; Ng, PS; Sin, WK; Tang, LC; Yuen, PM, 2001)		1.27

Toxicity

ExcerptReferenceRelevance
" Adverse gastrointestinal events were recorded more often in the Hemabate group."( A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage.
Gordon, H; Lamont, RF; Logue, M; Morgan, DJ, 2001)		0.54

Dosage Studied

ExcerptRelevanceReference
" An approach to dosing and choices of agent for the limitation of postpartum haemorrhage is suggested."( The use of uterotonic drugs during caesarean section.
Dresner, A; Dyer, RA; van Dyk, D, 2010)		0.36
" The carbetocin was administered as 100 µg intravenous dosage across the trials, while oxytocin was administered intravenously but at varied dosages."( Carbetocin for preventing postpartum haemorrhage.
Chong, YS; Samuel, M; Su, LL, 2012)		0.38
" The carbetocin was administered as 100 µg intravenous dosage across the trials, while oxytocin was administered intravenously but at varied dosages."( Carbetocin for preventing postpartum haemorrhage.
Chong, YS; Samuel, M; Su, LL, 2012)		0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (22.58)18.7374
1990's13 (20.97)18.2507
2000's23 (37.10)29.6817
2010's9 (14.52)24.3611
2020's3 (4.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.08 (24.57)
Research Supply Index4.51 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index95.18 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials24 (36.36%)5.53%
Reviews9 (13.64%)6.00%
Case Studies3 (4.55%)4.05%
Observational0 (0.00%)0.25%
Other30 (45.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage in Obese Women Undergoing Elective Cesarean Delivery [NCT03693599]Phase 41,200 participants (Actual)Interventional2018-10-01Completed
Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section [NCT02044549]Phase 4300 participants (Actual)Interventional2014-06-30Completed
A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section [NCT02046499]540 participants (Actual)Interventional2014-01-01Completed
Intramuscular Oxytocics: A Randomised Control Trial of Intramuscular Carbetocin, Syntocinon and Syntometrine for the Third Stage of Labour Following Vaginal Birth [NCT02216383]Phase 35,798 participants (Actual)Interventional2015-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
procaine
Procaine: A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016).. procaine : A benzoate ester, formally the result of esterification of 4-aminobenzoic acid with 2-diethylaminoethanol but formed experimentally by reaction of ethyl 4-aminobenzoate with 2-diethylaminoethanol.		1.9610benzoate ester;
substituted aniline;
tertiary amino compound		central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		1.9610penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
tromethamine
Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)		3.3911primary amino compound;
triol		buffer
dihydrostreptomycin sulfate
Dihydrostreptomycin Sulfate: A semi-synthetic aminoglycoside antibiotic that is used in the treatment of TUBERCULOSIS.		1.9610
oxytocin
Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.		17.027524heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
ergonovine
Ergonovine: An ergot alkaloid (ERGOT ALKALOIDS) with uterine and VASCULAR SMOOTH MUSCLE contractile properties.. ergometrine : A monocarboxylic acid amide that is lysergamide in which one of the hydrogens attached to the amide nitrogen is substituted by a 1-hydroxypropan-2-yl group (S-configuration). An ergot alkaloid that has a particularly powerful action on the uterus, its maleate (and formerly tartrate) salt is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced.		17.027524ergot alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound;
primary alcohol;
secondary amino compound;
tertiary amino compound		diagnostic agent;
fungal metabolite;
oxytocic;
toxin
dinoprost
Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.		3.7821monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
hemabate
carboprost tromethamine : The tromethamine salt of carboprost. It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.		8.3911
carboprost
Carboprost: A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of PREGNANCY.. carboprost : Prostaglandin F2alpha in which the hydrogen at position 15 is substituted by methyl (S configuration). It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.		4.3422hydroxy monocarboxylic acidabortifacient;
oxytocic
misoprostol
Misoprostol: A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties.. misoprostol : A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form.		14.7298
15-keto-13,14-dihydroprostaglandin f2alpha
15-keto-13,14-dihydroprostaglandin F2alpha: main metabolite of PGF2alpha in plasma after allergen provoked asthma; RN given refers to (5Z,9alpha,11alpha)-isomer; structure. 13,14-dihydro-15-keto-PGF2alpha : A prostaglandin Falpha obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin F2alpha.		1.9710ketone;
prostaglandins Falpha		metabolite
carbetocin
carbetocin : Oxytocin in which the hydrogen on the phenolic hydroxy group is substituted by methyl, the amino group on the cysteine residue is substituted by hydrogen, and the sulfur of the cysteine residue is replaced by a methylene group. A synthetic carba-analogue of oxytocin, it is used to control bleeding after giving birth. Like oxytocin, it causes contraction of the uterus.		10.78126heterodetic cyclic peptideoxytocic
cardiovascular agents
Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.		1.9310
ConditionIndicatedRelationship StrengthStudiesTrials
Delayed Postpartum Hemorrhage
[description not available]		022.1921522
Postpartum Hemorrhage
Excess blood loss from uterine bleeding associated with OBSTETRIC LABOR or CHILDBIRTH. It is defined as blood loss greater than 500 ml or of the amount that adversely affects the maternal physiology, such as BLOOD PRESSURE and HEMATOCRIT. Postpartum hemorrhage is divided into two categories, immediate (within first 24 hours after birth) or delayed (after 24 hours postpartum).		022.1921522
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		022.322624
Blood Pressure, High
[description not available]		05.0333
Puerperal Disorders
Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.		05.754
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		05.0333
Uterine Atony
[description not available]		02.4920
Uterine Inertia
Failure of the UTERUS to contract with normal strength, duration, and intervals during childbirth (LABOR, OBSTETRIC). It is also called uterine atony.		02.4920
Blood Loss, Postoperative
[description not available]		03.5311
Recrudescence
[description not available]		02.0510
Inversion of Uterus
[description not available]		02.6730
Complications, Labor
[description not available]		04.0431
Hemorrhage, Uterine
[description not available]		03.821
Uterine Hemorrhage
Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding.		03.821
Emesis, Postoperative
[description not available]		02.0510
Endometrial Diseases
[description not available]		02.0510
Uterine Diseases
Pathological processes involving any part of the UTERUS.		02.0510
Postoperative Nausea and Vomiting
Emesis and queasiness occurring after anesthesia.		02.0510
Bleeding
[description not available]		01.9410
Hemorrhage
Bleeding or escape of blood from a vessel.		01.9410
Infant, Newborn, Diseases
Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts.		01.9610
Edema, Pulmonary
[description not available]		01.9610
Pulmonary Edema
Excessive accumulation of extravascular fluid in the lung, an indication of a serious underlying disease or disorder. Pulmonary edema prevents efficient PULMONARY GAS EXCHANGE in the PULMONARY ALVEOLI, and can be life-threatening.		01.9610
Cardiovascular Stroke
[description not available]		0210
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).		0210
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.3911
Diathesis
[description not available]		03.3911
Cholera Infantum
[description not available]		03.3911
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		03.3911
Emesis
[description not available]		03.3911
Vomiting
The forcible expulsion of the contents of the STOMACH through the MOUTH.		03.3911
Complications, Pregnancy
[description not available]		0210
Circulatory Collapse
[description not available]		0210
Shock
A pathological condition manifested by failure to perfuse or oxygenate vital organs.		0210
Bovine Diseases
[description not available]		01.9610